环磷酰胺联合糖皮质激素在系统性红斑狼疮中的应用效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Cyclophosphamide combined with glucocorticoid in systemic lupus erythematosus (SLE).Methods A total of 82 SLE patients treated in Jiujiang First People′s Hospital from March 2018 to March 2020 were divided into observation group and control group according to the random number table method, with 41 cases in each group.The control group was treated with Prednisone, and the observation group was treated with Cyclophosphamide on the basis of the control group.The clinical efficacy, serum cytokine level, immunoglobulin level and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group, and the difference was statistically significant (P＜0.05).There were no significant differences in serum cytokine levels and immunoglobulin levels between the two groups before treatment (P＞0.05); after treatment, the interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-α (IFN-α), immunoglobulin A (IgA), immunoglobulin M (IgM) and immunoglobulin G (IgG) levels of the two groups were lower than those before treatment, and the differences were statistically significant (P＜0.05); after treatment, the levels of IL-6, IL-10, IFN-α, IgA, IgM, and IgG in the observation group were lower than those in the control group, and the differences were statistically significant (P＜0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Conclusion Cyclophosphamide combined with Prednisone can enhance the therapeutic effect of SLE, reduce the body′s inflammatory response, suppress excessive immune hyperactivity, stabilize the progression of the disease, and is safe and reliable.

Key words： Systemic lupus erythematosus Cyclophosphamide Glucocorticoids Serum cytokines Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Ling
	TANG Yan-hua
	LIU Ju

Cite this article:

LIU Ling,TANG Yan-hua,LIU Ju. Effect of Cyclophosphamide combined with glucocorticoid in systemic lupus erythematosus[J]. 中国当代医药, 2021, 28(29): 56-59.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I29/56

[1]	李力，徐照，吴春叶，等.甲基泼尼松龙联合环磷酰胺治疗对SLE 患者细胞因子，免疫球蛋白，补体水平的影响及疗效分析[J].检验医学与临床，2018，15（2）：176-178.
[2]	尚华，张德芬，何芳，等.糖皮质激素联合吗替麦考酚酯分散片对系统性红斑狼疮患者的疗效及对免疫功能的影响[J].现代生物医学进展，2018，18（7）：1326-1329.
[3]	陈宇璇，冯学兵，靳子义，等.环磷酰胺对系统性红斑狼疮预后的影响[J].中华风湿病学杂志，2019，23（8）：507-512.
[4]	俞韶华，马旗，党延玲.他克莫司联合环磷酰胺治疗系统性红斑狼疮疗效及对血清单核细胞趋化蛋白4、可溶性白细胞介素-2 受体影响[J].临床军医杂志，2019，47（3）：258-260.
[5]	中华医学会风湿病学分会.系统性红斑狼疮诊断及治疗指南[J].中华风湿病学杂志，2010，14（5）：342-346.
[6]	龙洁，王涛，朱长亮.西药联合免疫吸附法治疗系统性红斑狼疮肾炎的效果及对炎性细胞因子和免疫功能的影响[J].中国医药导报，2018，15（24）：63-66.
[7]	张文广.自拟中药益气养血补肾方治疗系统性红斑狼疮疗效观察[J].现代中西医结合杂志，2017，26（3）：255-258.
[8]	何尚映，林洁，黄鹏，等.他克莫司胶囊联合醋酸泼尼松龙片治疗系统性红斑狼疮的临床研究[J].中国临床药理学杂志，2017，33（5）：398-400.
[9]	周静，黄闯，彭凤玲.人免疫球蛋白联合醋酸泼尼松治疗系统性红斑狼疮的效果及对患者CD28，ICOS，Tim-1 表达的影响[J].中国麻风皮肤病杂志，2019，35（6）：334-337，341.
[10]	方钰，张伟，李莎，等.丙种球蛋白联合甲泼尼龙治疗系统性红斑狼疮的疗效及其对患儿Th 细胞因子的影响[J].海南医学，2019，30（8）：1031-1034.
[11]	其米，周可金，王诗钰，等.环磷酰胺联合泼尼松治疗系统性红斑狼疮患者疗效及其对血清细胞因子的影响[J].疑难病杂志，2017，16（10）：1021-1024.
[12]	杨晓菊，董静，雷蕾，等.系统性红斑狼疮孕妇外周血及脐血IL-6、IL-10 和IFN-α 水平的变化及评估新生儿免疫功能的价值[J].中国生育健康杂志，2018，29（1）：61-64.
[13]	闾志敏，顾菁，叶丽萍.泼尼松、环磷酰胺联合川芎嗪注射液对系统性红斑狼疮患者免疫功能及其他相关因子水平的影响[J].海南医学院学报，2019，25（11）：834-838.
[14]	秦登优，伍正彬，田恩，等.他克莫司联合环磷酰胺和糖皮质激素治疗狼疮性肾炎的疗效观察[J].医学研究杂志，2018，47（7）：141-144.
[15]	黄耀禹，段俗言，王静，等.环磷酰胺或霉酚酸酯联合糖皮质激素治疗对系统性红斑狼疮患者血细胞及疾病活动度的影响[J].江苏医药，2018，44（12）：1410-1413.